A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

NCT06930573 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

DRUG: AK112

Sponsor

The First Affiliated Hospital of Zhengzhou University